Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Cancer Res. 2014 Oct 15;74(23):6947–6957. doi: 10.1158/0008-5472.CAN-14-1592

Figure 7. Knockdown of NFATc1 in MC38Met cells decreases tumor incidence and liver metastases.

Figure 7

(A) Western Blot showing NFAT proteins in MC38Met+shCtrl and MC38Met+shNFATc1 cell lines, β-actin is used as a loading control and Ramos cell extract as positive control. (B) Analysis of NFATc1 specific mRNA in cells shown in (A) (C) Rates of trans-endothelial invasion for cells are shown in (A–B). Individual replicate wells from a representative experiment are plotted with the mean and the standard error of the mean (bars and whiskers). (D) Representative (n=14–15 mice/group) bioluminescence image corresponding day 21. (E) Summary of bioluminescence signal quantified at day 21. (F) Summary incidence of liver metastases. (G) Liver metastases measured by liver weight to body weight ratio at 21 days post-injection. *p<0.03, *** p<0.001, **** p<0.0001.